Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?

Key Points

• Gyre shares rose about 2% to roughly $7.84 intraday on light volume (down ~62% vs. average), trading near its 50- and 200-day moving averages with a market cap of about $760M.
• The stock carries a consensus analyst rating of "Hold" with a $17 consensus price target, but recent research notes are mixed—Weiss reaffirmed a sell, Wall Street Zen downgraded to hold, and Zacks cut to a strong sell (two buys vs. two sells overall).
• On fundamentals, Gyre slightly beat revenue expectations ($37.2M vs. $36.3M) but had an EPS miss ($0.04 vs. $0.08 expected) and a very high P/E (~784.8), reflecting elevated valuation expectations.

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shot up 2% during mid-day trading on Tuesday . The company traded as high as $7.92 and last traded at $7.84. 36,473 shares changed hands during trading, a decline of 62% from the average session volume of 96,938 shares. The stock had previously closed at $7.69.

Analyst Upgrades and Downgrades

Several brokerages have commented on GYRE. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen downgraded Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Finally, Zacks Research cut shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $17.00.

Gyre Therapeutics Stock Up 2.0%

The stock has a market cap of $760.17 million, a P/E ratio of 784.78 and a beta of 2.10. The company's 50 day moving average price is $7.67 and its two-hundred day moving average price is $7.70.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $37.20 million for the quarter, compared to analysts' expectations of $36.30 million. Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.

Institutional Trading of Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in Gyre Therapeutics during the 3rd quarter worth about $38,000. Bank of America Corp DE raised its holdings in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock valued at $46,000 after purchasing an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock worth $54,000 after purchasing an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Gyre Therapeutics in the 4th quarter worth approximately $77,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.